Please enable JavaScript to continue using this application.

Compare $ADMA vs $CLDX | Chartloom

Compare

$ADMA vs $CLDX

ADMA Biologics Inc · Celldex Therapeutics Inc

ADMA

ADMA Biologics Inc

CLDX

Celldex Therapeutics Inc

Compare $ADMA vs $CLDX

Comparing ADMA Biologics Inc and Celldex Therapeutics Inc

ADMAADMA Biologics Inc

CLDXCelldex Therapeutics Inc

ADMAADMA Biologics Inc

Market cap

$2.40B

P/E (TTM)

14.12x

Forward P/E (NTM)

12.78x

Forward P/S (NTM)

4.05x

Rev growth (TTM)

8.0%

YTD performance

-42.1%

52W performance

-29.1%

FCF yield

4.8%

CLDXCelldex Therapeutics Inc

Market cap

$2.35B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1,016.81x

Rev growth (TTM)

-97.3%

YTD performance

10.7%

52W performance

9.7%

FCF yield

-10.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ADMA

CLDX

Detailed metrics comparison

ADMA

ADMA Biologics Inc

CLDX

Celldex Therapeutics Inc

Market Cap

ADMA$2.40B

CLDX$2.35B

Enterprise Value

ADMA$2.46B

CLDX$2.30B

Price

ADMA$10.36

CLDX$29.89

P/E Ratio

ADMA14.12x

CLDXN/A

P/S Ratio

ADMA4.69x

CLDX14,848.52x

EV/Sales

ADMA4.81x

CLDX14,548.18x

EV/EBITDA

ADMA11.39x

CLDX0.00x

P/B Ratio

ADMA5.33x

CLDX3.48x

P/FCF Ratio

ADMA20.66x

CLDXN/A

EV/FCF

ADMA21.18x

CLDX-9.49x

PEG Ratio

ADMAN/A

CLDXN/A

Forward P/E (NTM)

ADMA12.78x

CLDXN/A

Forward P/S (NTM)

ADMA4.05x

CLDX1,016.81x

Revenue (TTM)

ADMA$512M

CLDX$158K

Revenue Growth (YoY)

ADMA8.0%

CLDX-97.3%

Forward Rev Growth

ADMA17.6%

CLDX637.2%

Gross Margin (TTM)

ADMA64.7%

CLDX17.6%

Operating Margin (TTM)

ADMA43.4%

CLDX0.0%

EBITDA Margin (TTM)

ADMA42.2%

CLDX-204070.9%

Net Margin (TTM)

ADMA33.0%

CLDX-190220.9%

FCF Margin (TTM)

ADMA22.7%

CLDX-153231.0%

Net Income (TTM)

ADMA$169M

CLDX$-301M

FCF (TTM)

ADMA$116M

CLDX$-242M

EPS (TTM)

ADMA$0.73

CLDX-$3.86

ROE (TTM)

ADMA39.6%

CLDX-5235.0%

ROA (TTM)

ADMA26.6%

CLDX-4761.0%

ROIC (TTM)

ADMA30.1%

CLDX-5235.0%

Cash

ADMA$136M

CLDX$47M

Debt

ADMA$197M

CLDX$0

Net Cash/Debt

ADMA$-61M

CLDX$47M

Current Ratio (TTM)

ADMA6.97x

CLDX11.82x

Quick Ratio (TTM)

ADMA3.62x

CLDX11.71x

Debt/Equity (TTM)

ADMA0.48x

CLDX0.00x

Debt/Assets (TTM)

ADMA0.0%

CLDX0.0%

Interest Coverage (TTM)

ADMAN/A

CLDXN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

CLDX0.00x

Beta

ADMA0.70

CLDX0.99

52W Performance

ADMA-29.1%

CLDX9.7%

YTD Performance

ADMA-42.1%

CLDX10.7%

% from 52W High

ADMA-49.4%

CLDX-33.8%

% from 52W Low

ADMA43.7%

CLDX35.2%

Asset Turnover (TTM)

ADMA0.81x

CLDX0.00x

FCF Yield (TTM)

ADMA4.8%

CLDX-10.3%

Earnings Yield (TTM)

ADMA7.0%

CLDX-12.8%

Dividend Yield (TTM)

ADMAN/A

CLDXN/A

Rule of 40

ADMA30.7

CLDX-153,328.3

EV/GP/RG

ADMA0.47

CLDX42.93

Ticker research

View ADMA research View CLDX research

Metric	ADMA ADMA Biologics Inc	CLDX Celldex Therapeutics Inc
Market & Valuation
Market Cap	$2.40B	$2.35B
Enterprise Value	$2.46B	$2.30B
Price	$10.36	$29.89
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	14,848.52x
EV/Sales	4.81x	14,548.18x
EV/EBITDA	11.39x	0.00x
P/B Ratio	5.33x	3.48x
P/FCF Ratio	20.66x	N/A
EV/FCF	21.18x	-9.49x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	N/A
Forward P/S (NTM)	4.05x	1,016.81x
Revenue & Growth
Revenue (TTM)	$512M	$158K
Revenue Growth (YoY)	8.0%	-97.3%
Forward Rev Growth	17.6%	637.2%
Profitability
Gross Margin (TTM)	64.7%	17.6%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	-204070.9%
Net Margin (TTM)	33.0%	-190220.9%
FCF Margin (TTM)	22.7%	-153231.0%
Net Income (TTM)	$169M	$-301M
FCF (TTM)	$116M	$-242M
EPS (TTM)	$0.73	-$3.86
ROE (TTM)	39.6%	-5235.0%
ROA (TTM)	26.6%	-4761.0%
ROIC (TTM)	30.1%	-5235.0%
Financial Health
Cash	$136M	$47M
Debt	$197M	$0
Net Cash/Debt	$-61M	$47M
Current Ratio (TTM)	6.97x	11.82x
Quick Ratio (TTM)	3.62x	11.71x
Debt/Equity (TTM)	0.48x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	0.99
52W Performance	-29.1%	9.7%
YTD Performance	-42.1%	10.7%
% from 52W High	-49.4%	-33.8%
% from 52W Low	43.7%	35.2%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	0.00x
FCF Yield (TTM)	4.8%	-10.3%
Earnings Yield (TTM)	7.0%	-12.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	-153,328.3
EV/GP/RG	0.47	42.93
Ticker research	View ADMA research	View CLDX research

Valuation

P/E Ratio

ADMA

14.12x

P/S Ratio

ADMA

4.69x

CLDX

14,848.52x

EV/FCF

CLDX

-9.49x

ADMA

21.18x

Growth & revenue

Revenue Growth TTM

ADMA

8.0%

CLDX

-97.3%

Forward Revenue Growth

CLDX

637.2%

ADMA

17.6%

Profitability & performance

Gross Margin

ADMA

64.7%

CLDX

17.6%

ROE

ADMA

39.6%

CLDX

-5235.0%

FCF Yield %

ADMA

4.8%

CLDX

-10.3%

52-Week Performance

CLDX

9.7%

ADMA

-29.1%

Detailed metrics comparison

ADMA

ADMA Biologics Inc

CLDX

Celldex Therapeutics Inc

Market Cap

ADMA$2.40B

CLDX$2.35B

Enterprise Value

ADMA$2.46B

CLDX$2.30B

Price

ADMA$10.36

CLDX$29.89

P/E Ratio

ADMA14.12x

CLDXN/A

P/S Ratio

ADMA4.69x

CLDX14,848.52x

EV/Sales

ADMA4.81x

CLDX14,548.18x

EV/EBITDA

ADMA11.39x

CLDX0.00x

P/B Ratio

ADMA5.33x

CLDX3.48x

P/FCF Ratio

ADMA20.66x

CLDXN/A

EV/FCF

ADMA21.18x

CLDX-9.49x

PEG Ratio

ADMAN/A

CLDXN/A

Forward P/E (NTM)

ADMA12.78x

CLDXN/A

Forward P/S (NTM)

ADMA4.05x

CLDX1,016.81x

Revenue (TTM)

ADMA$512M

CLDX$158K

Revenue Growth (YoY)

ADMA8.0%

CLDX-97.3%

Forward Rev Growth

ADMA17.6%

CLDX637.2%

Gross Margin (TTM)

ADMA64.7%

CLDX17.6%

Operating Margin (TTM)

ADMA43.4%

CLDX0.0%

EBITDA Margin (TTM)

ADMA42.2%

CLDX-204070.9%

Net Margin (TTM)

ADMA33.0%

CLDX-190220.9%

FCF Margin (TTM)

ADMA22.7%

CLDX-153231.0%

Net Income (TTM)

ADMA$169M

CLDX$-301M

FCF (TTM)

ADMA$116M

CLDX$-242M

EPS (TTM)

ADMA$0.73

CLDX-$3.86

ROE (TTM)

ADMA39.6%

CLDX-5235.0%

ROA (TTM)

ADMA26.6%

CLDX-4761.0%

ROIC (TTM)

ADMA30.1%

CLDX-5235.0%

Cash

ADMA$136M

CLDX$47M

Debt

ADMA$197M

CLDX$0

Net Cash/Debt

ADMA$-61M

CLDX$47M

Current Ratio (TTM)

ADMA6.97x

CLDX11.82x

Quick Ratio (TTM)

ADMA3.62x

CLDX11.71x

Debt/Equity (TTM)

ADMA0.48x

CLDX0.00x

Debt/Assets (TTM)

ADMA0.0%

CLDX0.0%

Interest Coverage (TTM)

ADMAN/A

CLDXN/A

Net Debt/EBITDA (TTM)

ADMA0.00x

CLDX0.00x

Beta

ADMA0.70

CLDX0.99

52W Performance

ADMA-29.1%

CLDX9.7%

YTD Performance

ADMA-42.1%

CLDX10.7%

% from 52W High

ADMA-49.4%

CLDX-33.8%

% from 52W Low

ADMA43.7%

CLDX35.2%

Asset Turnover (TTM)

ADMA0.81x

CLDX0.00x

FCF Yield (TTM)

ADMA4.8%

CLDX-10.3%

Earnings Yield (TTM)

ADMA7.0%

CLDX-12.8%

Dividend Yield (TTM)

ADMAN/A

CLDXN/A

Rule of 40

ADMA30.7

CLDX-153,328.3

EV/GP/RG

ADMA0.47

CLDX42.93

Ticker research

View ADMA research View CLDX research

Metric	ADMA ADMA Biologics Inc	CLDX Celldex Therapeutics Inc
Market & Valuation
Market Cap	$2.40B	$2.35B
Enterprise Value	$2.46B	$2.30B
Price	$10.36	$29.89
P/E Ratio	14.12x	N/A
P/S Ratio	4.69x	14,848.52x
EV/Sales	4.81x	14,548.18x
EV/EBITDA	11.39x	0.00x
P/B Ratio	5.33x	3.48x
P/FCF Ratio	20.66x	N/A
EV/FCF	21.18x	-9.49x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	12.78x	N/A
Forward P/S (NTM)	4.05x	1,016.81x
Revenue & Growth
Revenue (TTM)	$512M	$158K
Revenue Growth (YoY)	8.0%	-97.3%
Forward Rev Growth	17.6%	637.2%
Profitability
Gross Margin (TTM)	64.7%	17.6%
Operating Margin (TTM)	43.4%	0.0%
EBITDA Margin (TTM)	42.2%	-204070.9%
Net Margin (TTM)	33.0%	-190220.9%
FCF Margin (TTM)	22.7%	-153231.0%
Net Income (TTM)	$169M	$-301M
FCF (TTM)	$116M	$-242M
EPS (TTM)	$0.73	-$3.86
ROE (TTM)	39.6%	-5235.0%
ROA (TTM)	26.6%	-4761.0%
ROIC (TTM)	30.1%	-5235.0%
Financial Health
Cash	$136M	$47M
Debt	$197M	$0
Net Cash/Debt	$-61M	$47M
Current Ratio (TTM)	6.97x	11.82x
Quick Ratio (TTM)	3.62x	11.71x
Debt/Equity (TTM)	0.48x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.70	0.99
52W Performance	-29.1%	9.7%
YTD Performance	-42.1%	10.7%
% from 52W High	-49.4%	-33.8%
% from 52W Low	43.7%	35.2%
Efficiency & Yields
Asset Turnover (TTM)	0.81x	0.00x
FCF Yield (TTM)	4.8%	-10.3%
Earnings Yield (TTM)	7.0%	-12.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	30.7	-153,328.3
EV/GP/RG	0.47	42.93
Ticker research	View ADMA research	View CLDX research